TCI Wealth Advisors’s NovoCure NVCR Stock Holding History

TCI Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22	Closed	-$1.32K	–	1533
2023 Q1	$1.32K	Sell	22 -6	-21%	-$479	﹤0.01%	2059
2022 Q4	$2.05K	Hold	28	–	–	﹤0.01%	1970
2022 Q3	$2K	Buy	28 +6	+27%	+$468	﹤0.01%	1960
2022 Q2	$2K	Sell	22 -8	-27%	-$603	﹤0.01%	2019
2022 Q1	$3K	Sell	30 -73	-71%	-$5.38K	﹤0.01%	1896
2021 Q4	$8K	Buy	103 +102	+10,200%	+$10.2K	﹤0.01%	1346
2021 Q3	$0	Sell	1 -49	-98%	-$7.41K	﹤0.01%	2512
2021 Q2	$11K	Buy	50 +33	+194%	+$6.42K	﹤0.01%	916
2021 Q1	$2K	Buy	+17	New	+$2.69K	﹤0.01%	1822

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

TCI Wealth Advisors's NVCR Position: Q2 2023 in Review

TCI Wealth Advisors sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 22 shares — an estimated $1.32K sold.

TCI Wealth Advisors first reported a position in NVCR in Q1 2021 and held it in 9 quarters. The position peaked at $11K in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

TCI Wealth Advisors reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 22 NovoCure shares in Q2 2023, an estimated $1.32K.
TCI Wealth Advisors first reported a position in NovoCure in Q1 2021 and held it in 9 quarters.
TCI Wealth Advisors's NovoCure position peaked at $11K in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.